Clinical trials
Relapsed or Refractory Multiple Myeloma (RRMM) clinical trials
Below are recruiting relapsed or refractory multiple myeloma (rrmm) clinical trials, each written for real people, not researchers. We’re tracking 1,249 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06715436Recruiting
Ketogenic diet for multiple sclerosis
This study tests whether a ketogenic diet can help people with multiple sclerosis. You would follow a special high-fat, low-carb diet for a period, and the researchers will check its effects on your symptoms and overall health.
PaviaAges 18–60 - NCT07517185RecruitingPhase 2
Early aggressive treatment for relapsing multiple sclerosis
This trial tests whether treating relapsing multiple sclerosis (RRMS) aggressively and early with a specific medication can slow disease progression. You may qualify if you were recently diagnosed, have had recent disease activity, and are willing to take a strong immunosuppressive drug with regular MRI monitoring.
FalunAges 18–50 - NCT07510607RecruitingPhase 2
Metabolic imaging study for multiple sclerosis
This study tests a new imaging method using a special substance called hyperpolarized 13C pyruvate to see how it can help understand multiple sclerosis. You may join if you have relapsing-remitting MS, have not used disease-modifying treatments in the past two years, and are planning to start anti-CD20 therapy.
San Francisco, CaliforniaAges 18 years+ - NCT07471841RecruitingPhase 2
Olutasidenib for IDH1-mutated AML after venetoclax
This trial tests the drug olutasidenib for people with a specific type of acute myeloid leukemia (AML) that has come back or not responded to treatment. It is for patients who have already received the drug venetoclax and have an IDH1 mutation in their leukemia cells.
Winston-Salem, North CarolinaAges 18 years+ - NCT06751134RecruitingPhase 1
Engineered immune cells for relapsed neuroblastoma in children
This trial tests a new type of immune cell therapy (called CNK-UT) for children whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if these cells can find and attack the cancer. Participation may be an option if your child's tumor has a specific marker (B7-H3) and their overall health is stable enough.
Nanjing, JiangsuAges 1–12 - NCT07420959RecruitingPhase 1/Phase 2
ABBV-383 for Waldenström macroglobulinemia that came back
This trial tests a new drug called ABBV-383 for people with Waldenström macroglobulinemia that has returned or stopped responding to treatment. The drug is given as an infusion and aims to attack the cancer cells. This might help if you've already tried a BTK inhibitor.
Rochester, MinnesotaAges 18 years+ - NCT07376772Recruiting
Wearable vibration therapy for arm and hand function in multiple sclerosis
This study tests if a wearable device that gently vibrates the arm can improve hand and arm function in people with multiple sclerosis. You would use the device at home while doing daily activities.
Gainesville, FloridaAges 18–100 - NCT07356154RecruitingPhase 1/Phase 2
Study of revumenib and mezigdomide for leukemia
This trial tests two experimental drugs, revumenib and mezigdomide, for people with acute leukemia that has certain genetic changes (NPM1, KMT2A, or NUP98) and has come back or not responded to prior treatment. The goal is to see if this combination can help control the leukemia.
Duarte, CaliforniaAges 12 years+ - NCT07353216Recruiting
Testing ofatumumab for relapsing multiple sclerosis
This trial tests if ofatumumab can help people with relapsing multiple sclerosis (RMS) by measuring its effect on nerve damage markers in the blood. It aims to see if the drug is safe and effective for controlling relapses and slowing disease activity.
Guangzhou, GuangdongAges 18 years+ - NCT07318129Recruiting
Indole-3-propionic acid for multiple sclerosis
This trial tests an oral supplement called indole-3-propionic acid to see if it can help people with relapsing-remitting multiple sclerosis (RRMS). It involves taking the supplement daily and having regular MRI scans to monitor your MS.
Glostrup MunicipalityAges 18–65 - NCT06581081Recruiting
CAR-T therapy with or without stem cell transplant for B-cell leukemia
This trial tests a CD19-targeted CAR-T cell therapy (S1904) for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. After CAR-T, some patients may go on to a stem cell transplant. The goal is to see if the CAR-T can lead to remission and who needs a transplant.
Beijing, Beijing MunicipalityAges 12–65 - NCT06874530Recruiting
Isatuximab for multiple myeloma with 1q21 abnormality
This trial tests if adding the drug isatuximab to standard treatments helps people whose multiple myeloma has returned or stopped responding, especially if their cancer cells have an extra copy of a certain gene (1q21). The study checks how well these drugs work together.
BolognaAges 18 years+ - NCT07284433RecruitingPhase 1/Phase 2
Donor cell therapy for B-cell blood cancers
This trial tests a new treatment made from donor cells that target two proteins (CD19 and CD20) found on certain blood cancer cells. It may be an option for people whose B-cell lymphoma or chronic lymphocytic leukemia has come back or hasn't responded to at least two prior treatments.
Chicago, IllinoisAges 18 years+ - NCT07225985RecruitingPhase 1/Phase 2
Pralatrexate, bendamustine, and radiation before donor stem cell transplant for T-cell lymphoma
This trial tests a combination of two chemotherapy drugs (pralatrexate and bendamustine) plus total-body radiation before a donor stem cell transplant for people with T-cell lymphoma that has come back or hasn't responded to treatment. The goal is to see if this approach can help destroy the lymphoma and allow the donor cells to take hold safely.
Seattle, WashingtonAges 18 years+ - NCT07178431RecruitingPhase 1/Phase 2
CAR T-cell therapy for worsening multiple sclerosis
This trial tests a new treatment called MB-CART2019.1, which uses your own immune cells to fight multiple sclerosis. It is for people with progressive or worsening MS who have not responded well to other treatments.
BerlinAges 18–55 - NCT06956326RecruitingPhase 2
Early rehab for multiple sclerosis relapse recovery
This trial tests whether early and specialized rehabilitation can help people with multiple sclerosis recover better after a motor relapse. It is for people who are already staying at a Danish MS Hospital for rehab.
HaslevAges 18 years+ - NCT07125872RecruitingPhase 2
New drug for relapsed B-cell lymphoma
This trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has come back after at least two prior treatments. It may help if you've already had rituximab or a similar antibody therapy.
JohannesburgAges 18 years+ - NCT07087002RecruitingPhase 1
GPC2-CAR T cells for children and young adults with relapsed medulloblastoma
This trial tests a new type of cell therapy called GPC2-CAR T cells for children and young adults whose medulloblastoma or related brain tumor has come back or not responded to standard treatment. The goal is to see if these specially designed immune cells can find and attack the tumor.
Palo Alto, CaliforniaAges 1–30 - NCT06034561RecruitingPhase 2
Bortezomib for relapsed or refractory acute lymphoblastic leukemia
This trial tests a chemotherapy combination that includes bortezomib for people whose acute lymphoblastic leukemia (ALL) has come back or not responded to previous treatments. It aims to offer a new option for those who haven't tried bortezomib before.
São Paulo, São PauloAges 16–60 - NCT07085676RecruitingPhase 1
CAR-T cell therapy for autoimmune diseases that resist treatment
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
JerusalemAges 18–80 - NCT03401879Recruiting
Study eye blood-flow changes in multiple sclerosis
This study measures how blood flow in the eye changes in people with relapsing-remitting multiple sclerosis (RRMS) who previously had optic neuritis. The goal is to understand eye/brain blood-flow signals and how they may relate to MS.
Vienna, AustriaAges 18 years+ - NCT07025564RecruitingPhase 1
MiRisten for relapsed or refractory AML
This phase 1 trial tests a new treatment called MiRisten for people with acute myeloid leukemia (AML) that has come back or not responded to previous treatments. The goal is to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06947083RecruitingPhase 2
Elranatamab after cilta-cel for high-risk multiple myeloma
This trial tests a new drug, elranatamab, for people with multiple myeloma who recently received a CAR-T cell therapy (cilta-cel) but still have high-risk features. The goal is to see if elranatamab can help keep the cancer from coming back.
Tampa, FloridaAges 18 years+ - NCT06919900Recruiting
Learning fall-resistant skills in multiple sclerosis
This trial tests if practicing slips and trips can help people with multiple sclerosis learn to prevent falls. You will be exposed to controlled slips and trips to improve your balance and walking safety.
Atlanta, GeorgiaAges 45–89
Hear when a new Relapsed or Refractory Multiple Myeloma (RRMM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory multiple myeloma (rrmm)?
- Yes. Clin2 currently lists 1,249 recruiting relapsed or refractory multiple myeloma (rrmm) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory multiple myeloma (rrmm) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory multiple myeloma (rrmm) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.